TABLE 2

Overview of Administered Activities and Estimated Organ and Lymphoma Doses

	Patient no.
Parameter	1	2	3	4	5	6
Pretherapy dosimetry
¹⁷⁷Lu-pentixather (MBq)	224	224	200	208	200	211
Kidney max_mL (Gy/GBq ¹⁷⁷Lu)	0.8	2.9	1.3	0.8	^*	1.3
Liver (Gy/GBq ¹⁷⁷Lu)	0.2	0.6	0.7	0.4	0.6	0.9
Spleen (Gy/GBq ¹⁷⁷Lu)	0.3	0.8	0.7	1.0	1.7	0.7
Bone marrow max_mL (Gy/GBq ¹⁷⁷Lu)	^†	^†	^*	4.8	2.4	0.9
Extramedullary lesion max_mL (Gy/GBq ¹⁷⁷Lu)	0.9	1.9	4.5		5.5	1.9
RLT
⁹⁰Y-pentixather (GBq)	5.3	2.8	4.3	6.5	5.8	6.2
Added RLT with ¹⁸⁸Re-anti-CD66 (GBq)					5.6
Added RLT with ⁹⁰Y-Zevalin (GBq)						1.4
Posttherapy dosimetry^‡
Kidney max_mL (no protection) (Gy/GBq ⁹⁰Y)	3.5	11.3	4.9	3.8	^*	5.7
Liver (Gy/GBq ⁹⁰Y)	0.9	1.8	1.6	1.3	1.6	2.0
Spleen (Gy/GBq ⁹⁰Y)	1.2	1.8	1.6	3.4	3.6	1.8
Bone marrow (Gy/GBq ⁹⁰Y)	^†	^†	^*	11.4	5.1	1.9
Extramedullary lesion max_mL (Gy/GBq ⁹⁰Y)	3.9	5.3	10.4		16.7	7.1
Kidney max_mL (with protection^¶) (Gy)	11.2	19.2	12.9	14.6	^*	20.9
Liver (Gy)	5.0	5.1	7.1	8.4	9.5	12.2
Spleen (Gy)	6.6	5.2	7.0	21.8	20.7	11.1
Bone marrow max_mL (Gy)	^†	^†	^*	73.8	29.4	11.7
Extramedullary lesion max_mL (Gy)	20.9	15.0	45.2		96.5	43.5

↵* Not evaluable because of malignant structures.
↵† No visible tracer accumulation.
↵‡ 90Y-pentixather, recalculated from pretherapeutic dosimetry.
↵¶ 40% reduction of absorbed radiation dose of kidneys by coinfusion of amino acid solution (arginine/lysine).